Objective: Streptococcus (S.) pyogenes is common cause of acute tonsillitis. Lipoteichoic acid (LTA), which is a common constitute of the cell surface of most gram positive bacteria, is known to act as a substance of bacterial site for adherence to epithelium and antiserum to LTA is reported to inhibit bacterial attachment to epithelial cells in vitro. Cholera toxin subunit B (CT-B) is known to be a mucosal adjuvant. The purpose of this study is to investigate whether intranasal immunization with LTA and CT-B may be a possible candidate for vaccine formulation. Methods: Six-week-old male BALB/c mice were assigned to 3 experimental groups, mice immunized with LTA and CT-B, with LTA alone and with phosphate buffered saline (PBS) as a control. Immunizations were performed intranasally every 2 days for 2 weeks in every group. At the 21 days after immunization, sera, pharyngeal washings and pharyngeal epithelial cells were taken. The levels of serum IgG and pharyngeal IgA antibodies to LTA were measured by enzyme-linked immunosorbent assay (ELISA). The adherence rates of S. pyogenes pretreated by pharyngeal washings to pharyngeal epithelial cells from the mice were determined by in vitro adherence assay.
Introduction
Recurrent episode of acute tonsillitis is a common problem in infectious disorders during childhood. Bacterial adherence to tonsillar or pharyngeal epithelium may be a potential cause of recurrent tonsillitis (RT) [1, 2] . Humoral immunity of the host may be another cause of recurrence of this phlogistic condition. Pharyngeal secretory IgA has been reported to be lower in children with RT [1] .
Streptococcus (S.) pyogenes is a common pathogen of acute tonsillitis [3] .
Lipoteichoic acid (LTA), a constituent of the cell surface of most streptococci including S. pyogenes, is characterized as glycolipid-linked polymers of glycerol phosphate units [4, 5] .
LTA is homogenous among strains and species in structure and antigenicity, and to act as a substance in the bacterial site for adherence to mucosa [6] [7] [8] [9] . It has been reported that in vitro streptococcal adherence to human buccal cells or hydroxyapatite was significantly reduced by treatment with anti-LTA antibody obtained from rabbit immunized systemically with LTA, demonstrating that the antibody had an inhibiting activity against bacterial adherence to epithelium [6, 7] . Therefore, LTA has been proposed as a possible candidate for vaccine formulation for S. pyogenes infections.
Recently, we demonstrated decreased serum IgG and pharyngeal IgA antibody levels specific to streptococcal LTA in young children with RT [10] . This immunologic failure may be potential cause of RT in childhood. It has been demonstrated that oral administration of conjugate with LTA from S. pyogenes and lipopolysaccharide from Klebsilella pneumonia enhanced the IgA and IgG antibody synthesis in the lung and in mice [11] .
However, there is no attempt to enhance pharyngeal IgA response specific to streptococcal LTA and to investigate its protective effect against streptococcal infection.
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Cholera toxin B subunit (CT-B) containing trace amount of the holotoxin is a potent mucosal immunogen, partly because of its high-binding to the receptor GM1 ganglioside, facilitating uptake at mucosal surfaces of both CT-B and molecules linked to it [12] . Several studies with animals have shown that CT-B used as a carrier for various protein or carbohydrate antigens can enhance the mucosal immunogenicity for the linked antigens [13, 14] . Recent studies have shown that intranasal immunization of antigen mixed with CT-B induces effectively an antigen-specific serum IgG response as well as a nasal or nasopharyngeal IgA response [15, 16] .
In this study, on the basis of the backgrounds, we performed intranasal immunization of streptococcal LTA with an adjuvant CT-B in mice. In addition, we measured antibody levels to LTA in serum IgG and in pharyngeal IgA, and assessed streptococcal adherence to pharyngeal cells from the mice.
Materials and Methods

Animals and Immunization
Six-week-old male BALB/c mice were obtained from CLEA Japan Inc. (Tokyo, Japan). They were maintained under the specific pathogen free conditions and provided food and water ad libidum.
Immunization was performed as described previously [16] . BALB/c mice were randomly assigned to 3 experimental groups (A to C). Group A mice were intranasally immunized with 10 µl of phosphate buffered saline (PBS) containing 100 µg of LTA purified from S. pyogenes (Sigma Immuno Chemical Co., St. Louis, Mo., USA) and mucosal adjuvant cholera toxin (CT) (Cholera toxin B subunit supplement with 0.17% of CT; Sigma). Group B mice were intranasally immunized with 10 µl of PBS containing 100 µg of LTA alone. Group C mice were intranasally administered with 10 µl of PBS alone as a control. Immunizations were performed on days 0, 2, 4, 6, 8, 10, 12 and 14 in every group.
On days 21 days, sera, pharyngeal washings and pharyngeal epithelial cells were taken and subject to assay.
Sampling
Blood was obtained transcardially. Serum samples were separated and stored at - 
Measurement of antibodies specific to LTA
The antibody levels to LTA in sera and pharyngeal washings were measured by enzyme-linked immunosorbent assay (ELISA) as described previously [17] with some modification. Wells of flat-bottomed microplates (Nunc-Immuno Plate MaxiSorp, Roskilde, Denmark) were coated with 50 µl of 10 µg/ml LTA in carbonate buffer (pH 9.6) and were incubated at 4°C overnight. The material was then aspirated and 100 µl of 3% gelatin in PBS was added to each well to cover the unreacted sites. After standing for 60 minutes at 37°C, the wells were washed three times with PBS containing 0.05% polysorbate 20 (Tween 20; PBS-T). These wells were then added to 50 µl of serum samples diluted 1: To ensure the specificity of this assay, we measured the residual antibody activity of standard mouse serum with bacterial antigens. 
Statistics
Analysis of data was performed using appropriate nonparametric test procedures.
Comparisons between over 2 groups were tested by the Friedman's test or the Kruskal-Wallis analysis with the Bonferroni method for calculation of p-value. Statistical tests were based on a level of significance of p<0.05.
Results
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Antibody responses in sera and pharyngeal washings
The 
Discussion
S. pyogenes is common is a common pathogen of acute tonsillitis [3] . It has been reported that in vitro streptococcal adherence to human buccal cells or hydroxyapatite was significantly reduced by treatment with anti-LTA antibody obtained from rabbit immunized systemically with LTA, demonstrating that the antibody had an inhibiting activity against bacterial adherence to epithelium [6, 7] . Furthermore, LTA is homogenous among strains and species in structure [6] [7] [8] [9] , indicating that the antibody to LTA may response to a number of species and strains of streptococci. These are reason why we chose LTA as a candidate antigen for vaccine formulation against streptococcal tonsillitis.
Kofler and Wolf [11] demonstrated that oral administration of conjugate with LTA from S. pyogenes and lipopolysaccharide from Klebsilella pneumonia enhanced the IgA and IgG antibody synthesis in the lung of mice. Several reports have demonstrated increased attachment of S. pyogenes to tonsillar or pharyngeal epithelium during acute tonsillitis [1, 2] ,
suggesting bacterial adherence to epithelium may be one of the determinants for streptococcal tonsillitis. Most pathogens enter the host through the mucosal membranes and induce a local mucosal immune response, mainly represented by secretory IgA [18] . In pharyngeal secretions, secretory IgA is the predominant immunoglobulin and plays a role in the inhibition of bacterial adherence to pharyngeal mucosa [19] . Systemic immunity by IgGspecific antibody does not influence bacterial adherence to respiratory epithelium [20] .
Therefore, induction of pharyngeal IgA response is important to inhibit streptococcal adherence to epithelium, resulting in prevention for streptococcal tonsillitis.
Cholera toxin B subunit (CT-B) is reported to be as a mucosal adjuvant facilitating uptake at mucosal surfaces of both CT-B and molecules linked to it [12] . Recently a number of investigators demonstrated that intranasal immunization of antigens mixed with CT-B evoked effectively an antigen-specific serum IgG response as well as a pharyngeal IgA response [15, 16, 19] . In our study, we succeeded to induce a good pharyngeal IgA response as well as systemic IgG response to LTA by the intranasal immunization with LTA and CT-B. The detectable levels of pharyngeal anti-LTA IgA antibody observed in control mice may represent preexisting antibody due to prior exposure to LTA of oral streptococci in the normal flora. This preexisting antibody has been observed also in the other experiment previously reported elsewhere [11] .
In the adherence study, pretreatment with pharyngeal washings from the mice immunized with LTA and CT-B, which contained high levels of anti-LTA IgA antibody, decreased streptococcal adherence to pharyngeal cells from the mice with any immunization.
This may be mainly due to effect of anti-LTA secretory IgA antibody in the pharyngeal washings. The affects of preexisting cell bound antibody induced as a result of immunization is likely to be minor, because the number of organisms pretreated with pharyngeal washings from control mice was not different between pharyngeal cells from LTA and CT-B
immunized mice and those from control mice. However, we cannot exclude influence of factors other than secretory IgA [21] . Recent study has suggested that locally synthesized IgG, different from its serum counterpart, could complement secretory IgA in the defense against pathogens [22] .
Our present data suggest that intranasal immunization of LTA with CT-B may be an effective approach to protect against streptococcal adherence to pharyngeal epithelial cells, resulting in preventing streptococcal tonsillitis. On the other hand, intracutaneous immunization with LTA failed to evoke specific antibody response to LTA and to protect against dental caries in rhesus monkeys [23] . Our present study is a first attempt to develop vaccine formation for streptococcal tonsillitis. However, this is still preliminary and there is a number of problems to be dissolved. For example, we previously demonstrated decreased pharyngeal IgA antibody levels to streptococcal LTA in children with recurrent tonsillitis [10] , suggesting that pharyngeal antibody response to LTA vaccine may be reduced in those children. The CT-B used as an adjuvant in this study is toxic in humans. Recently, mutant cholera toxin that is not toxic in humans has been reported to be effective to evoke mucosal immune response [24] . Additional studies for antigen delivery system using non-toxic mucosal adjuvant will be needed to develop vaccine formation for humans.
